Clinical Trials Browser

Terminated × Parkinson Disease 4, Autosomal Dominant Lewy Body × pembrolizumab × Clear all

NCT03924869 2025-12-11

KEYNOTE-867

Phase 3 Terminated

448 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04135352 2024-11-12

V938-001

Phase 1 Terminated

35 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasm Metastasis

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04152863 2024-08-06

V937-011

Phase 2 Terminated

85 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05709821 2024-04-24

IMM60 and Pembrolizumab in Melanoma and NSCLC

Phase 1/2 Terminated

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03019588 2023-03-30

MK-3475-063

Phase 3 Terminated

94 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03739138 2022-02-28

MK-4621-002

Phase 1 Terminated

30 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03361228 2020-05-21

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Phase 1/2 Terminated

5 enrolled 4 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03099161 2019-06-05

MK-3814A-062

Phase 1 Terminated

10 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms